BLISSGVS vs LAURUSLABS: Stock Comparison
Laurus Labs Limited is the larger company by market capitalisation. Bliss GVS Pharma Limited shows a lower P/E, faster revenue growth and a higher net margin, while Laurus Labs Limited shows a higher ROE, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BLISSGVS leads 7; LAURUSLABS leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | BLISSGVS | LAURUSLABS |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | BLISSGVS | LAURUSLABS |
|---|---|---|
| Live Price | ₹527.1 | ₹1,802 |
| Day Change | 0.68% | -1.26% |
| Volume | 3.93 L | 14.02 L |
| 52-Week High | ₹553 | ₹1,870.8 |
| 52-Week Low | ₹118 | ₹823.1 |
| Distance from 52W High | -4.68% | -3.68% |
Valuation
| Metric | BLISSGVS | LAURUSLABS |
|---|---|---|
| Market Cap | ₹6,080 Cr | ₹96,799 Cr |
| P/E Ratio | 44.69x | 89.61x |
| P/B Ratio | 5.1x | 18.48x |
| EPS | ₹11.99 | ₹16.46 |
| Book Value | ₹107.21 | ₹98.16 |
| Dividend Yield | 0.19% | 0.19% |
Growth
| Metric | BLISSGVS | LAURUSLABS |
|---|---|---|
| Revenue Growth (TTM YoY) | 29.8% | 5.3% |
| EPS Growth (TTM YoY) | 124.7% | 19.4% |
| Qtr Sales Growth | 13% | 5.31% |
| Qtr Profit Growth | 108% | 19.5% |
Profitability & Leverage
| Metric | BLISSGVS | LAURUSLABS |
|---|---|---|
| ROE | 0% | 18.3% |
| ROCE | 11.7% | 17.8% |
| Net Margin | 13.93% | 13.76% |
| Operating Margin | 12.82% | 26.2% |
| Debt to Equity | 1.77x | 0.48x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | BLISSGVS | LAURUSLABS |
|---|---|---|
| Promoter Holding | 35.01%▼ 0.35 pp | 27.47%▼ 0.02 pp |
| FII Holding | 8.07%▼ 2.38 pp | 28%▲ 2.18 pp |
| DII Holding | 9.47%▲ 4.43 pp | 13.74%▼ 0.23 pp |
| Public Holding | 47.45%▼ 1.7 pp | 30.78%▼ 1.93 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Bliss GVS Pharma Limited and Laurus Labs Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.